Bone Biologics Co. (NASDAQ:BBLGW – Get Free Report)’s share price dropped 64.9% during trading on Tuesday . The company traded as low as $4.70 and last traded at $20.80. Approximately 1,388 shares traded hands during trading, a decline of 41% from the average daily volume of 2,343 shares. The stock had previously closed at $59.22.
Bone Biologics Stock Down 64.9 %
The business has a fifty day moving average of $55.71 and a 200 day moving average of $50.54.
Bone Biologics Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein. The company's NELL-1/DBM, an osteopromotive recombinant protein that provides target specific control over bone regeneration. It also develops NELL-1/DBM Fusion Device for use in spinal fusion procedures in skeletally mature patients with spinal degenerative disc disease at one level from L2-S1.
Further Reading
- Five stocks we like better than Bone Biologics
- How to Most Effectively Use the MarketBeat Earnings Screener
- Hims & Hers Earnings Could Be a Game Changer—What to Do Now
- Quiet Period Expirations Explained
- DeepSeek IPO Remains Far Off—Investors Eye 4 Chinese AI Stocks
- 3 REITs to Buy and Hold for the Long Term
- Mortgage Market Bottom? Why Rocket Companies Could Be a Buy
Receive News & Ratings for Bone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.
